Editorial Open Access
Cancer: disease, drugs and diets – an opinion
Vishnu Kumar Sahu1,4,*, Swati M2, Anil Kumar Soni3
- 1Department of Chemistry, Maharani Lal Kunwari Post Graduate College, Tulshipur Road, Balrampur-271201 (U.P.), India
- 2BND Division, AcSIR, CSIR- National Physical Laboratory, Dr K. S. Krishnan Marg, New Delhi-110012, India
- 3Department of Chemistry, Shia Post Graduate College, Sitapur Road, Lucknow-226020 (U.P), India
- 4Chemistry Department, Shia Intermediate College, Sitapur Road, Lucknow-226020 (U.P.), India
Corresponding Author
Vishnu Kumar Sahu, vishnukr_sahu@rediffmail.com
Received Date: April 06, 2026
Accepted Date: April 13, 2026
Sahu VK, Swati, Soni AK. Cancer: disease, drugs and diets – an opinion. Arch Clin Toxicol. 2026;8(1):11-13.
Copyright: © 2026 Sahu VK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
How many mutations does it take to make a uveal melanoma?
Uveal melanoma (UM) is a rare cancer that affects the choroid and, less frequently, the ciliary body or the iris (for recent reviews see [1-3]). Despite a profound knowledge of the oncogenic mechanisms behind UM tumorigenesis and despite an accurate cytogenetic and molecular prognosis, only limited advances have been made in UM therapy.
Positive-DAT and autoimmune manifestations in patients with JAK2V617F mutation
Myeloproliferative neoplasms (MPN) are occasionally associated with autoimmune manifestations. The prevalence of positive direct antiglobulin test (DAT) in patients with JAK2V617F mutation is not yet known.
Genetic mutations in the molecular pathogenesis of gastrointestinal stromal tumor
Gastrointestinal stromal tumors are mesenchymal tumors which predominantly originate from the interstitial cells of Cajal in the intestinal lining. Around ~85% of malignant GISTs possess activating mutations in the tyrosine kinase receptors KIT or PDGFRA. The driver mutations in genes other than KIT or PDGFRA account for around 15% GISTs and belong to highly heterogeneous groups called wild-type GISTs. Around 20–40% of WT-GISTS are deficient for the succinate dehydrogenase complex (SDHA, SDHB, SDHC, SDHD).
BRCA1 and BRCA2 mutation variants in early breast cancer confer added prognostic information
Metastatic breast cancer to brain carries poor prognostic features with increased risks of occurrence in Tripple- negative and HER- positive breast tumors. In addition, tumors with mutated BRCA tumors, carry as well increased metastatic incidence. However, new clinical evidence suggest distinct clinical features between BRCA1 or BRCA2 mutated breast cancer and brain metastasis. Review of literature may help characterize the distinctive differences between BRCA1 or BRCA2 breast tumors and subsequent metastasis to brain.
A new population screening program for BRCA mutations in Israel – Attitudes and barriers among Ashkenazi Jewish women
Israeli Jewish women of Ashkenazi ancestry have a high BRCA mutation carrier rate. Therefore, recently, Israel included free genetic testing among all Jewish women with Ashkenazi ancestry, 25 yrs. and older in its public health system. The aim of this study was to assess the intention of eligible women to be tested for BRCA mutations, and to find factors that may affect their decision.